Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over dieting.
Not Many Employers Cover GLP-1 Weight Loss Drugs
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
WeightWatchers to offer compounded GLP-1 weight-loss drugs
WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,
Balancing the costs of GLP-1 weight loss drug coverage: New CBO report has some answers
According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs for Medicare, but this could have a big effect on all employers health plans as well.
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.
Offering Wegovy and other weight loss drugs on Medicare could cost $35 billion
Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).
Medical News Today
1h
GLP-1 drugs like Ozempic may protect brain health, several studies show
A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...
1d
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
3d
on MSN
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.
11h
Inside Nestlé’s launch of a food brand for GLP-1 users—and how the packaging and design came together
When it came to deciding what kinds of foods Vital Pursuit would sell, the team turned to another Nestlé brand, Life Cuisine, for inspiration. Life Cuisine was rolled out in 2020 as a sibling brand to ...
1d
The Crackdown on Compounded GLP-1 Meds Has Begun
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
2d
on MSN
WW International surges as Morgan Stanley says GLP-1 entry 'not too late'
WW International (NASDAQ:WW) shares surged more than 20% in early trading on Wednesday after Morgan Stanley said the ...
JD Supra
3d
GLP-1 Drugs: FDA Removes Lilly’s Zepbound® and Mounjaro® (tirzepatide injection) from its Drug Shortage List
On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...
FiercePharma
4d
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Weight Watchers
NASDAQ
Food and Drug Administration
Ozempic
Novo Nordisk
Feedback